Global Ocular Drug Delivery System Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2022 to 2028

Description

List of Tables

Value Market Research deeply researched the Global Ocular Drug Delivery System Market to foresee a significant growth in the industry over the upcoming years. The global ocular drug delivery system market report provides a complete industry analysis, market size, market share, growth trends, and forecasts for 2023 to 2028. The report starts with a detailed market introduction and an executive summary that highlights the report's key growth numbers. The subsequent chapters discuss the value chain of the market, Porter's Five Forces Model, and market attractiveness analysis. An exclusive chapter on COVID-19 impact analysis has been added to understand how the market has responded to the pandemic.

The market dynamics section of the report elaborates the current market drivers, restraints along with the challenges/risks and upcoming opportunities. This section can be of high interest for any company's strategists and new product development department. The global ocular drug delivery system market study segments the market and provides the market size in terms of revenue and/ or sales. This data is bifurcated by region and later by countries. The data is collected through detailed primary interviews and industry experts across the world. The detailed methodology can be seen in our sample reports. These market estimates are also influenced by the latest social, political and economic changes along with the current market dynamics that are affecting this ocular drug delivery system market.

The next sections of the ocular drug delivery system market report studies the market competitiveness and profiles some key market players/manufacturers. These sections are knowledgeable for understanding the competitor's product-line, their financials, recent developments and the top market share owners in the industry.

Countries Covered in the report are as below:

North America - United States, Canada, and Mexico

Europe - United Kingdom, Germany, France, Italy, Russia, Spain & Rest of Europe

Asia-Pacific - China, India, Japan, South Korea, Australia & Rest of APAC

Latin America - Brazil, Argentina, Peru, Chile & Rest of Latin America

Middle East and Africa - Saudi Arabia, UAE, Israel, South Africa

Market Segmentation in the report is as below-

By Technology

Topical

Iontophoresis (Ocular Insert(Erodible and Non-Erodible), and Intraocular Implants(Biodegradable and Non-Biodegradable)

In Situ Gel & Punctal Plugs

Others

By Formulation Type

Liposomes & Nanoparticles

Solution

Emulsion

Suspension

Ointment

By Disease Type

Glaucoma

Diabetic Retinopathy

Dry Eye Syndrome

Macular Degeneration

Cataract

Diabetic Macular Edema

Others

By End Users

Hospitals

Ophthalmic Clinics

Ambulatory Surgical Centers

Homecare Settings

Product Code: VMR11215637

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . OCULAR DRUG DELIVERY SYSTEM - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 By Technology
- 3.7.2 By Formulation Type
- 3.7.3 By Disease Type
- 3.7.4 By End Users
- 3.7.5 By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL OCULAR DRUG DELIVERY SYSTEM MARKET ANALYSIS BY TECHNOLOGY

6.1 Overview by Technology
6.2 Historical and Forecast Data
6.3 Analysis by Technology
6.4 Topical Market by Regions
6.5 Iontophoresis Market by Regions
6.6 Ocular Insert Market by Regions
6.7 Intraocular Implants Market by Regions
6.8 In Situ Gel & Punctal Plugs Market by Regions
6.9 Others Market by Regions

7 . GLOBAL OCULAR DRUG DELIVERY SYSTEM MARKET ANALYSIS BY FORMULATION TYPE

7.1 Overview by Formulation Type
7.2 Historical and Forecast Data
7.3 Analysis by Formulation Type
7.4 Liposomes & Nanoparticles Market by Regions
7.5 Solution Market by Regions
7.6 Emulsion Market by Regions
7.7 Suspension Market by Regions
7.8 Ointment Market by Regions

8 . GLOBAL OCULAR DRUG DELIVERY SYSTEM MARKET ANALYSIS BY DISEASE TYPE

8.1 Overview by Disease Type
8.2 Historical and Forecast Data
8.3 Analysis by Disease Type
8.4 Glaucoma Market by Regions
8.5 Diabetic Retinopathy Market by Regions
8.6 Dry Eye Syndrome Market by Regions
8.7 Macular Degeneration Market by Regions
8.8 Cataract Market by Regions
8.9 Diabetic Macular Edema Market by Regions
8.10. Others Market by Regions

9 . GLOBAL OCULAR DRUG DELIVERY SYSTEM MARKET ANALYSIS BY END USERS

9.1 Overview by End Users
9.2 Historical and Forecast Data
9.3 Analysis by End Users
9.4 Hospitals Market by Regions
9.5 Ophthalmic Clinics Market by Regions
9.6 Ambulatory Surgical Centers Market by Regions
9.7 Homecare Settings Market by Regions

10 . GLOBAL OCULAR DRUG DELIVERY SYSTEM MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America
- 10.3.1. Overview, Historic and Forecast Data
- 10.3.2. North America By Segment
- 10.3.3. North America By Country
- 10.3.4. United State
- 10.3.5. Canada
- 10.3.6. Mexico
10.4. Europe
- 10.4.1. Overview, Historic and Forecast Data
- 10.4.2. Europe by Segment
- 10.4.3. Europe by Country
- 10.4.4. United Kingdom
- 10.4.5. France
- 10.4.6. Germany
- 10.4.7. Italy
- 10.4.8. Russia
- 10.4.9. Rest Of Europe
10.5. Asia Pacific
- 10.5.1. Overview, Historic and Forecast Data
- 10.5.2. Asia Pacific by Segment
- 10.5.3. Asia Pacific by Country
- 10.5.4. China
- 10.5.5. India
- 10.5.6. Japan
- 10.5.7. South Korea
- 10.5.8. Australia
- 10.5.9. Rest Of Asia Pacific
10.6. Latin America
- 10.6.1. Overview, Historic and Forecast Data
- 10.6.2. Latin America by Segment
- 10.6.3. Latin America by Country
- 10.6.4. Brazil
- 10.6.5. Argentina
- 10.6.6. Peru
- 10.6.7. Chile
- 10.6.8. Rest of Latin America
10.7. Middle East & Africa
- 10.7.1. Overview, Historic and Forecast Data
- 10.7.2. Middle East & Africa by Segment
- 10.7.3. Middle East & Africa by Country
- 10.7.4. Saudi Arabia
- 10.7.5. UAE
- 10.7.6. Israel
- 10.7.7. South Africa
- 10.7.8. Rest Of Middle East And Africa

11 . COMPETITIVE LANDSCAPE OF THE OCULAR DRUG DELIVERY SYSTEM COMPANIES

11.1. Ocular Drug Delivery System Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF OCULAR DRUG DELIVERY SYSTEM INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. Taiwan Liposome Company, Ltd.
- 12.3.1. Company Overview
- 12.3.2. Financials
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Valeant Pharmaceuticals International, Inc.
- 12.4.1. Company Overview
- 12.4.2. Financials
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. Ocular Therapeutix, Inc.
- 12.5.1. Company Overview
- 12.5.2. Financials
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Graybug Vision Inc.
- 12.6.1. Company Overview
- 12.6.2. Financials
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. Clearside Biomedical, Inc.
- 12.7.1. Company Overview
- 12.7.2. Financials
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. EyeGate Pharma
- 12.8.1. Company Overview
- 12.8.2. Financials
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Envisia Therapeutics
- 12.9.1. Company Overview
- 12.9.2. Financials
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Alimera Sciences
- 12.10.1. Company Overview
- 12.10.2. Financials
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Allergan Plc
- 12.11.1. Company Overview
- 12.11.2. Financials
- 12.11.3. Products
- 12.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies